Expression of cyclooxygenase-1 and -2 in XXXX @entity14 .

@entity1 @entity5230 @entity5 @entity1421 @entity117 @entity105 @entity14 @entity9859 @entity3352 @entity2247 @entity694
Several studies indicate that nonsteroidal anti-inflammatory drugs including @entity3352 , @entity117 , sulindac, and @entity5230 reduce the risk of @entity694 . Furthermore, nonsteroidal anti-inflammatory drugs that inhibit the cyclooxygenase (COX) enzyme were shown to inhibit the development of @entity694 in animal models of @entity105 . Non-steroidal anti-inflammatory drugs inhibit the enzymatic activity of both the constitutive ( @entity9859 ) and inducible ( @entity2247 ) isoforms of COX enzyme. We have investigated the expression of @entity9859 and @entity2247 polypeptides in @entity1 @entity694 tissues using immunohistochemistry. Enhanced @entity2247 expression was observed in @entity694 tissues from 15 subjects with clinically diagnosed @entity14 . Marked @entity2247 expression was observed in @entity5 cells, inflammatory cells, vascular endothelium, and fibroblasts of the lesional tissues compared with the nonlesional and normal colon tissues. The extent and intensity of the immunoreactive @entity2247 in @entity5 cells was much greater than that of the other cell types. In contrast, the expression of @entity9859 polypeptide was weak in both normal and cancerous specimens. These data suggest that the enhanced expression of the @entity2247 gene in @entity694 tissues may contribute to the enhanced synthesis of @entity1421 by the @entity694 tissues. Enhanced expression of @entity2247 may play a role in the pathogenesis of @entity694 . Furthermore, selective inhibition of @entity2247 may prove to be more efficacious in the retardation of @entity694 development.
